Compare
Xtant Medical Holdings, Inc. vs InfuSystem Holdings, Inc vs Neuronetics, Inc. vs Pulmonx Corp
| Latest fiscal year | Xtant Medical Holdings, Inc. XTNT | InfuSystem Holdings, Inc INFU | Neuronetics, Inc. STIM | Pulmonx Corp LUNG |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $133.93M | $143.44M | $149.16M | $90.50M |
| Revenue growth (YoY) | +14.2% | +6.4% | +99.2% | +8.0% |
| Gross margin | 62.9% | 56.0% | 48.5% | 74.2% |
| Operating margin | 5.4% | 8.3% | -21.1% | -59.3% |
| Net margin | 3.7% | 4.6% | -26.1% | -59.7% |
| Net income | $4.97M | $6.63M | -$39.00M | -$54.00M |
| EPS (Diluted) | $0.03 | $0.31 | -$0.59 | -$1.33 |
| Operating cash flow | $12.55M | $24.41M | -$20.37M | -$32.38M |
| Free cash flow | $10.16M | $23.85M | -$21.18M | -$32.83M |
| Cash & equivalents | $17.05M | $3.19M | $28.13M | $69.75M |
| Total assets | $94.14M | $100.56M | $141.55M | $129.29M |
| Total liabilities | $43.19M | $43.23M | $115.31M | $75.17M |
| Shareholders' equity | $50.95M | $57.33M | $22.38M | $54.12M |
| Return on year-end equity | 9.8% | 11.6% | -174.3% | -99.8% |
| Shares outstanding | 140.04M | 20.21M | 68.99M | 41.67M |
Revenue, most recent five fiscal years
| Fiscal year | Xtant Medical Holdings, Inc. | InfuSystem Holdings, Inc | Neuronetics, Inc. | Pulmonx Corp |
|---|---|---|---|---|
| Latest | $133.93M Ended 2025-12-31 | $143.44M Ended 2025-12-31 | $149.16M Ended 2025-12-31 | $90.50M Ended 2025-12-31 |
| 1 year earlier | $117.27M Ended 2024-12-31 | $134.86M Ended 2024-12-31 | $74.89M Ended 2024-12-31 | $83.79M Ended 2024-12-31 |
| 2 years earlier | $91.30M Ended 2023-12-31 | $125.78M Ended 2023-12-31 | $71.35M Ended 2023-12-31 | $68.67M Ended 2023-12-31 |
| 3 years earlier | $57.97M Ended 2022-12-31 | $109.91M Ended 2022-12-31 | $65.21M Ended 2022-12-31 | $53.66M Ended 2022-12-31 |
| 4 years earlier | $55.26M Ended 2021-12-31 | $102.38M Ended 2021-12-31 | $55.31M Ended 2021-12-31 | $48.42M Ended 2021-12-31 |